Current EV
Historical EV

Regeneron Pharmaceuticals Inc., current enterprise value calculation

Current share price (P)	$547.36
No. shares of common stock outstanding	107,965,497
US$ in thousands
Common equity (market value)¹	59,095,994)
Add: Preferred Stock, par value $.01 per share; issued and outstanding: none (per books)	—)
Total equity	59,095,994)
Add: Finance lease liabilities, current portion (per books)	—)
Add: Long-term debt (per books)	1,984,400)
Add: Finance lease liabilities, excluding current portion (per books)	720,000)
Total equity and debt	61,800,394)
Less: Cash and cash equivalents	2,488,200)
Less: Marketable securities	6,524,300)
Enterprise value (EV)	52,787,894)

Based on: 10-K (reporting date: 2024-12-31).

¹ Common equity (market value) = Share price × No. shares of common stock outstanding
= 547.36 × 107,965,497

Regeneron Pharmaceuticals Inc., EV calculation

	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Share price^1, 2	$716.72	$936.33	$780.86	$622.36	$494.90
No. shares of common stock outstanding¹	109,324,682	109,761,896	109,325,532	108,539,282	107,131,899
US$ in thousands
Common equity (market value)³	78,355,186)	102,773,356)	85,367,935)	67,550,508)	53,019,577)
Add: Preferred Stock, par value $.01 per share; issued and outstanding: none (book value)	—)	—)	—)	—)	—)
Total equity	78,355,186)	102,773,356)	85,367,935)	67,550,508)	53,019,577)
Add: Finance lease liabilities, current portion (book value)	—)	—)	—)	719,700)	—)
Add: Long-term debt (book value)	1,984,400)	1,982,900)	1,981,400)	1,980,000)	1,978,500)
Add: Finance lease liabilities, excluding current portion (book value)	720,000)	720,000)	720,000)	—)	717,200)
Total equity and debt	81,059,586)	105,476,256)	88,069,335)	70,250,208)	55,715,277)
Less: Cash and cash equivalents	2,488,200)	2,730,000)	3,105,900)	2,885,600)	2,193,700)
Less: Marketable securities	6,524,300)	8,114,800)	4,636,400)	2,809,100)	1,393,300)
Enterprise value (EV)	72,047,086)	94,631,456)	80,327,035)	64,555,508)	52,128,277)

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

¹ Data adjusted for splits and stock dividends.

² Closing price as at the filing date of Regeneron Pharmaceuticals Inc. Annual Report.

³ 2024 Calculation
Common equity (market value) = Share price × No. shares of common stock outstanding
= 716.72 × 109,324,682

Equity Trends: The common equity, which is equivalent to total equity in this dataset, exhibits a consistent upward trend over four consecutive years from December 31, 2020, through December 31, 2023. The value increased from approximately $53.0 billion to about $102.8 billion, nearly doubling over this period. However, in the final year ending December 31, 2024, there is a notable decline, with equity falling to approximately $78.4 billion. This represents a significant reduction of nearly 24% from the prior year, reversing the prior expanding equity trend.
Total Equity and Debt: Total equity and debt increases steadily from $55.7 billion at the end of 2020 to about $105.5 billion by the end of 2023. The growth mirrors the earlier equity gains and suggests an increasing scale of financing through both equity and debt. Similar to total equity, this metric experiences a marked contraction in 2024, declining to approximately $81.1 billion. This decline may indicate debt reduction, equity erosion, or a combination of both, given the simultaneous decrease in total equity.
Enterprise Value (EV): The enterprise value follows a comparable growth scenario from 2020 through 2023, rising from $52.1 billion to $94.6 billion, reflecting improving firm valuation and increased company size. In 2024, EV declines to $72.0 billion, a decrease of about 24%. This pattern of decline aligns with the reductions observed in total equity and total capital, suggesting comprehensive valuation compression potentially due to market factors, operational performance, or capital structure adjustments.
General Observations: The data suggests a phase of robust growth in market value and capital structure size over four years, followed by a significant correction or contraction in the most recent year. The declines in 2024 across common equity, total equity and debt, and enterprise value are substantial and may warrant further investigation into underlying causes such as market conditions, business performance, or strategic corporate actions impacting valuation and financing.

Download chart

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)

Enterprise Value (EV)

Current Enterprise Value (EV)

Historical Enterprise Value (EV)